Substance Use & Drug Information News Briefs
February 7, 2025
CEU Course of the Week:
Advanced Street Drug Pharmacology
HEADLINES
FDA approves new non-opioid medication for moderate to severe pain
Even where cannabis is legal, product safety isn't guaranteed
Generations flip the script on alcohol
How do Mexico, Canada, and China affect fentanyl flowing into the U.S.?
A secure base: Harm reduction as attachment therapy
Inside the DEA's Chicago drug testing lab
Editorial: Beyond buprenorphine in the ED: Leveraging lessons from 10 years of implementation
Denver proposes licensing rules for psychedelic centers
Opioid use disorder in sexually and gender diverse populations: Can we do better?
NEW PAPERS AND REPORTS
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain (FDA, February 5, 2025)
Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose (Nature Communications, February 6, 2025)
Changes in Incident Schizophrenia Diagnoses Associated With Cannabis Use Disorder After Cannabis Legalization (Free pdf. JAMA Network Open, February 5, 2025)
Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl (Free pdf download. JAMA Network Open, January 25, 2025)
mHealth Incentivized Adherence Plus Patient Navigation (MIAPP): protocol for a pilot randomized controlled trial to improve linkage and retention on buprenorphine for hospitalized patients with methamphetamine use and opioid use disorder (Addiction Science and Clinical Practice, January 30, 2025)
Find more research here
JRW Behavioral Health Services | 2746 Reese Avenue | Evanston, IL 60201 US
Unsubscribe | Update Profile | Constant Contact Data Notice